

Isabelle Cremer

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2856203/publications.pdf>

Version: 2024-02-01

97
papers

9,035
citations

44042

48
h-index

46771

89
g-index

101
all docs

101
docs citations

101
times ranked

14106
citing authors

#	ARTICLE	IF	CITATIONS
1	SMARCA4-deficient lung carcinoma is an aggressive tumor highly infiltrated by FOXP3+ cells and neutrophils. Lung Cancer, 2022, 169, 13-21.	0.9	9
2	Metabolic features of cancer cells impact immunosurveillance. , 2021, 9, e002362.		11
3	To Vaccinate or not: Influenza Virus and Lung Cancer Progression. Trends in Cancer, 2021, 7, 573-576.	3.8	11
4	Immunodynamics of explanted human tumors for immunoœoncology. EMBO Molecular Medicine, 2021, 13, e12850.	3.3	9
5	Autophagy Modulation by Viral Infections Influences Tumor Development. Frontiers in Oncology, 2021, 11, 743780.	1.3	5
6	Assessment of NK cell-mediated cytotoxicity by flow cytometry after rapid, high-yield isolation from peripheral blood. Methods in Enzymology, 2020, 631, 277-287.	0.4	0
7	Natural killer cells in the human lung tumor microenvironment display immune inhibitory functions. , 2020, 8, e001054.		54
8	NK cells in the tumor microenvironment: Prognostic and theranostic impact. Recent advances and trends. Seminars in Immunology, 2020, 48, 101407.	2.7	31
9	Chemoradiotherapy efficacy is predicted by intra-tumour CD8+/FoxP3+ double positive T cell density in locally advanced N2 nonœsmall-cell lung carcinoma. European Journal of Cancer, 2020, 135, 221-229.	1.3	11
10	Side-by-side comparison of flow cytometry and immunohistochemistry for detection of calreticulin exposure in the course of immunogenic cell death. Methods in Enzymology, 2020, 632, 15-25.	0.4	3
11	Toll-Like Receptors (TLRs) in the Tumor Microenvironment (TME): A Dragon-Like Weapon in a Non-fantasy Game of Thrones. Advances in Experimental Medicine and Biology, 2020, 1263, 145-173.	0.8	16
12	Abstract 4304: Radio-chemotherapy efficacy is predicted by intra-tumor CD8+FoxP3+ double positive T cell density in locally advanced non-small cell lung carcinoma. , 2020, , .		0
13	NK Cells in the Human Lungs. Frontiers in Immunology, 2019, 10, 1263.	2.2	57
14	Proposal for a Combined Histomolecular Algorithm to Distinguish Multiple Primary Adenocarcinomas from Intrapulmonary Metastasis in Patients with Multiple Lung Tumors. Journal of Thoracic Oncology, 2019, 14, 844-856.	0.5	55
15	Calreticulin exposure correlates with robust adaptive antitumor immunity and favorable prognosis in ovarian carcinoma patients. , 2019, 7, 312.		52
16	Toll like receptor 7 expressed by malignant cells promotes tumor progression and metastasis through the recruitment of myeloid derived suppressor cells. Oncoimmunology, 2019, 8, e1505174.	2.1	37
17	Abstract 573: Mutations found by targeted next generation sequencing is associated with intra-tumor immune profile and may predict response to anti-PD1 therapy in lung adenocarcinoma. , 2019, , .		0
18	Impaired Tumor-Infiltrating T Cells in Patients with Chronic Obstructive Pulmonary Disease Impact Lung Cancer Response to PD-1 Blockade. American Journal of Respiratory and Critical Care Medicine, 2018, 198, 928-940.	2.5	62

#	ARTICLE	IF	CITATIONS
19	Expression of LLT1 and its receptor CD161 in lung cancer is associated with better clinical outcome. <i>Oncolmmunology</i> , 2018, 7, e1423184.	2.1	38
20	TNFR2/BIRC3-TRAF1 signaling pathway as a novel NK cell immune checkpoint in cancer. <i>Oncolmmunology</i> , 2018, 7, e1386826.	2.1	26
21	<i>TP53, STK11</i>, and <i>EGFR</i> Mutations Predict Tumor Immune Profile and the Response to Anti-“PD-1 in Lung Adenocarcinoma. <i>Clinical Cancer Research</i> , 2018, 24, 5710-5723.	3.2	257
22	Immunopathogenesis of the Anti-Synthetase Syndrome. <i>Critical Reviews in Immunology</i> , 2018, 38, 263-278.	1.0	2
23	Abstract 5752: Protumoral and pro-metastatic effects of TLR7 in lung cancer. , 2018, , .		0
24	Toll-like receptor stimulation in cancer: A pro- and anti-tumor double-edged sword. <i>Immunobiology</i> , 2017, 222, 89-100.	0.8	172
25	Prognostic impact of the expression of NCR1 and NCR3 NK cell receptors and PD-L1 on advanced non-small cell lung cancer. <i>Oncolmmunology</i> , 2017, 6, e1163456.	2.1	30
26	Polyfunctionality of bona fide resident lung CD69 + natural killer cells. <i>Journal of Allergy and Clinical Immunology</i> , 2017, 140, 317-318.	1.5	4
27	Calreticulin exposure by malignant blasts correlates with robust anticancer immunity and improved clinical outcome in AML patients. <i>Blood</i> , 2016, 128, 3113-3124.	0.6	107
28	Immune contexture and histological response after neoadjuvant chemotherapy predict clinical outcome of lung cancer patients. <i>Oncolmmunology</i> , 2016, 5, e1255394.	2.1	62
29	Involvement of NK Cells and NKp30 Pathway in Antisynthetase Syndrome. <i>Journal of Immunology</i> , 2016, 197, 1621-1630.	0.4	26
30	Trial Watch: Immunotherapy plus radiation therapy for oncological indications. <i>Oncolmmunology</i> , 2016, 5, e1214790.	2.1	64
31	Calreticulin expression: Interaction with the immune infiltrate and impact on survival in patients with ovarian and non-small cell lung cancer. <i>Oncolmmunology</i> , 2016, 5, e1177692.	2.1	52
32	Intratumoral Immune Cell Densities Are Associated with Lung Adenocarcinoma Gene Alterations. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2016, 194, 1403-1412.	2.5	48
33	Trial Watch-“Immunostimulation with cytokines in cancer therapy. <i>Oncolmmunology</i> , 2016, 5, e1115942.	2.1	52
34	Calreticulin Expression in Human Non-“Small Cell Lung Cancers Correlates with Increased Accumulation of Antitumor Immune Cells and Favorable Prognosis. <i>Cancer Research</i> , 2016, 76, 1746-1756.	0.4	164
35	Trial Watch-“Oncolytic viruses and cancer therapy. <i>Oncolmmunology</i> , 2016, 5, e1117740.	2.1	88
36	Trial Watch-“Small molecules targeting the immunological tumor microenvironment for cancer therapy. <i>Oncolmmunology</i> , 2016, 5, e1149674.	2.1	46

#	ARTICLE	IF	CITATIONS
37	Trial Watch: Immunostimulation with Toll-like receptor agonists in cancer therapy. <i>Oncolmmunology</i> , 2016, 5, e1088631.	2.1	104
38	Abstract A124: Protumoral effects of TLR7 in lung tumors. <i>Cancer Immunology Research</i> , 2016, 4, A124-A124.	1.6	1
39	Prognostic and Predictive Value of DAMPs and DAMP-Associated Processes in Cancer. <i>Frontiers in Immunology</i> , 2015, 6, 402.	2.2	135
40	Characterization of the Microenvironment in Positive and Negative Sentinel Lymph Nodes from Melanoma Patients. <i>PLoS ONE</i> , 2015, 10, e0133363.	1.1	14
41	Trial watch: Tumor-targeting monoclonal antibodies for oncological indications. <i>Oncolmmunology</i> , 2015, 4, e985940.	2.1	47
42	Trial Watch: Peptide-based anticancer vaccines. <i>Oncolmmunology</i> , 2015, 4, e974411.	2.1	97
43	Trial Watch: Immunomodulatory monoclonal antibodies for oncological indications. <i>Oncolmmunology</i> , 2015, 4, e1008814.	2.1	102
44	Trial Watch: Immunogenic cell death inducers for anticancer chemotherapy. <i>Oncolmmunology</i> , 2015, 4, e1008866.	2.1	237
45	Profiling of the Three Circulating Monocyte Subpopulations in Human Obesity. <i>Journal of Immunology</i> , 2015, 194, 3917-3923.	0.4	92
46	IFN- γ / β Receptor Signaling Promotes Regulatory T Cell Development and Function under Stress Conditions. <i>Journal of Immunology</i> , 2015, 194, 4265-4276.	0.4	69
47	Negative prognostic value of high levels of intracellular poly(ADP-ribose) in non-small cell lung cancer. <i>Annals of Oncology</i> , 2015, 26, 2470-2477.	0.6	20
48	Trial Watch: Adoptive cell transfer for oncological indications. <i>Oncolmmunology</i> , 2015, 4, e1046673.	2.1	29
49	Trial watch: Naked and vectored DNA-based anticancer vaccines. <i>Oncolmmunology</i> , 2015, 4, e1026531.	2.1	26
50	Dual roles of TLR7 in the lung cancer microenvironment. <i>Oncolmmunology</i> , 2015, 4, e991615.	2.1	27
51	Trial watch. <i>Oncolmmunology</i> , 2014, 3, e29030.	2.1	51
52	Consensus guidelines for the detection of immunogenic cell death. <i>Oncolmmunology</i> , 2014, 3, e955691.	2.1	686
53	Trial Watch. <i>Oncolmmunology</i> , 2014, 3, e29179.	2.1	76
54	Trial Watch. <i>Oncolmmunology</i> , 2014, 3, e27048.	2.1	69

#	ARTICLE	IF	CITATIONS
55	Trial Watch. <i>Oncolimmunology</i> , 2014, 3, e28185.	2.1	36
56	Trial Watch:. <i>Oncolimmunology</i> , 2014, 3, e28694.	2.1	95
57	Mature Cytotoxic CD56 ^{bright} /CD16 ⁺ Natural Killer Cells Can Infiltrate Lymph Nodes Adjacent to Metastatic Melanoma. <i>Cancer Research</i> , 2014, 74, 81-92.	0.4	85
58	Trial watch: Dendritic cell-based anticancer therapy. <i>Oncolimmunology</i> , 2014, 3, e963424.	2.1	62
59	Dendritic Cells in Tumor-Associated Tertiary Lymphoid Structures Signal a Th1 Cytotoxic Immune Contexture and License the Positive Prognostic Value of Infiltrating CD8 ⁺ T Cells. <i>Cancer Research</i> , 2014, 74, 705-715.	0.4	466
60	T Cell-Derived IL-22 Amplifies IL-1 β -Driven Inflammation in Human Adipose Tissue: Relevance to Obesity and Type 2 Diabetes. <i>Diabetes</i> , 2014, 63, 1966-1977.	0.3	197
61	TLR7 Promotes Tumor Progression, Chemotherapy Resistance, and Poor Clinical Outcomes in Non-Small Cell Lung Cancer. <i>Cancer Research</i> , 2014, 74, 5008-5018.	0.4	83
62	Trial Watch. <i>Oncolimmunology</i> , 2014, 3, e27878.	2.1	134
63	Presence of B Cells in Tertiary Lymphoid Structures Is Associated with a Protective Immunity in Patients with Lung Cancer. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2014, 189, 832-844.	2.5	564
64	Trial Watch. <i>Oncolimmunology</i> , 2014, 3, e28344.	2.1	31
65	The New Histologic Classification of Lung Primary Adenocarcinoma Subtypes Is a Reliable Prognostic Marker and Identifies Tumors With Different Mutation Status. <i>Chest</i> , 2014, 146, 633-643.	0.4	80
66	Systemic Inflammation, Nutritional Status and Tumor Immune Microenvironment Determine Outcome of Resected Non-Small Cell Lung Cancer. <i>PLoS ONE</i> , 2014, 9, e106914.	1.1	137
67	The Immune Microenvironment of Human Tumors: General Significance and Clinical Impact. <i>Cancer Microenvironment</i> , 2013, 6, 117-122.	3.1	119
68	Immune Infiltrates Are Prognostic Factors in Localized Gastrointestinal Stromal Tumors. <i>Cancer Research</i> , 2013, 73, 3499-3510.	0.4	277
69	Characteristics and Clinical Impacts of the Immune Environments in Colorectal and Renal Cell Carcinoma Lung Metastases: Influence of Tumor Origin. <i>Clinical Cancer Research</i> , 2013, 19, 4079-4091.	3.2	301
70	Trial watch. <i>Oncolimmunology</i> , 2013, 2, e25771.	2.1	150
71	Phenotypic and Functional Characteristics of Blood Natural Killer Cells from Melanoma Patients at Different Clinical Stages. <i>PLoS ONE</i> , 2013, 8, e76928.	1.1	58
72	Lung Tumor Microenvironment Induces Specific Gene Expression Signature in Intratumoral NK Cells. <i>Frontiers in Immunology</i> , 2013, 4, 19.	2.2	56

#	ARTICLE	IF	CITATIONS
73	Tumor microenvironment in NSCLC suppresses NK cells function. <i>Oncolmmunology</i> , 2012, 1, 244-246.	2.1	34
74	Prognostic Impact of Vitamin B6 Metabolism in Lung Cancer. <i>Cell Reports</i> , 2012, 2, 257-269.	2.9	122
75	Prognostic Impact of Vitamin B6 Metabolism in Lung Cancer. <i>Cell Reports</i> , 2012, 2, 1472.	2.9	0
76	Abstract LB-497: Primary tumor localization determines the metastatic immune profile. , 2012, , .		0
77	Abstract LB-498: Density of tertiary lymphoid structures is associated with activated and effector-memory T lymphocyte infiltration in human lung tumor. , 2012, , .		0
78	CD14 ^{dim} CD16 ⁺ and CD14 ⁺ CD16 ⁺ Monocytes in Obesity and During Weight Loss. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2011, 31, 2322-2330.	1.1	210
79	Characterization of Chemokines and Adhesion Molecules Associated with T cell Presence in Tertiary Lymphoid Structures in Human Lung Cancer. <i>Cancer Research</i> , 2011, 71, 6391-6399.	0.4	245
80	Alternatively spliced NKp30 isoforms affect the prognosis of gastrointestinal stromal tumors. <i>Nature Medicine</i> , 2011, 17, 700-707.	15.2	282
81	Tumor microenvironment is multifaceted. <i>Cancer and Metastasis Reviews</i> , 2011, 30, 13-25.	2.7	95
82	Profound Coordinated Alterations of Intratumoral NK Cell Phenotype and Function in Lung Carcinoma. <i>Cancer Research</i> , 2011, 71, 5412-5422.	0.4	404
83	Immune Infiltration in Human Cancer: Prognostic Significance and Disease Control. <i>Current Topics in Microbiology and Immunology</i> , 2010, 344, 1-24.	0.7	193
84	Triggering of TLR7 and TLR8 expressed by human lung cancer cells induces cell survival and chemoresistance. <i>Journal of Clinical Investigation</i> , 2010, 120, 1285-1297.	3.9	191
85	Characterization of immune functions in TRAF4-deficient mice. <i>Immunology</i> , 2008, 124, 562-574.	2.0	25
86	Adipose tissue transcriptomic signature highlights the pathological relevance of extracellular matrix in human obesity. <i>Genome Biology</i> , 2008, 9, R14.	13.9	372
87	NKG2C is a major triggering receptor involved in the V α 1 T cell-mediated cytotoxicity against HIV-infected CD4 T cells. <i>Aids</i> , 2008, 22, 217-226.	1.0	56
88	TRAF4 overexpression is a common characteristic of human carcinomas. <i>Oncogene</i> , 2007, 26, 142-147.	2.6	72
89	Long-lived immature dendritic cells mediated by TRANCE-RANK interaction. <i>Blood</i> , 2002, 100, 3646-3655.	0.6	78
90	A non-classical ISRE/ISGF3 pathway mediates induction of RANTES gene transcription by type I IFNs. <i>FEBS Letters</i> , 2002, 511, 41-45.	1.3	24

#	ARTICLE	IF	CITATIONS
91	Mannose Receptor Ligand-Positive Cells Express the Metalloprotease Decysin in the B Cell Follicle. <i>Journal of Immunology</i> , 2001, 167, 5052-5060.	0.4	31
92	Retrovirally Mediated IFN- $\hat{2}$ Transduction of Macrophages Induces Resistance to HIV, Correlated with Up-Regulation of RANTES Production and Down-Regulation of C-C Chemokine Receptor-5 Expression. <i>Journal of Immunology</i> , 2000, 164, 1582-1587.	0.4	48
93	Inhibition of Human Immunodeficiency Virus Transmission to CD4+T Cells after Gene Transfer of Constitutively Expressed Interferon $\hat{2}$ to Dendritic Cells. <i>Human Gene Therapy</i> , 2000, 11, 1695-1703.	1.4	5
94	Acquired Constitutive Expression of Interferon beta after Gene Transduction Enhances Human Immunodeficiency Virus Type 1-Specific Cytotoxic T Lymphocyte Activity by a RANTES-Dependent Mechanism. <i>Human Gene Therapy</i> , 1999, 10, 1803-1810.	1.4	8
95	Interferon- $\hat{2}$ -Induced Human Immunodeficiency Virus Resistance in CD34+Human Hematopoietic Progenitor Cells: Correlation with a Down-Regulation of CCR-5 Expression. <i>Virology</i> , 1999, 253, 241-249.	1.1	17
96	Interferon \hat{A} transduction of peripheral blood lymphocytes from HIV-infected donors increases Th1-type cytokine production and improves the proliferative response to recall antigens. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1997, 94, 11595-11600.	3.3	29
97	Antiviral Activity of Autocrine Interferon- $\hat{2}$ Requires the Presence of a Functional Interferon Type I Receptor. <i>Journal of Interferon and Cytokine Research</i> , 1995, 15, 785-789.	0.5	12